SavedAdd your journal

Journals / Journal of Surgery and Medicine / 2021 / Cilt: 5 - Sayı: 9

Effects of antenatal magnesium sulfate use for neuroprotection on cardiorespiratory complications during the early neonatal period in preterm infants

Nuran ÜSTÜN
Meryem HOCAOĞLU
Abdulkadir TURGUT
Fahri OVALI
Pages
843–847
Publication Date
2021-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Mothers in the MgSO4 group were more likely to have preeclampsia and antenatal steroid treatment, while their infants were younger in gestation and weighed less (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aim: Antenatal magnesium sulfate (MgSO4) treatment is widely used for fetal neuroprotection in women at risk of preterm delivery.
📊
Key Findings & Data:Possible adverse effects of MgSO4 include respiratory depression and delay in closure of ductus arteriosus by antagonism of calcium channels.
💡
Conclusion & Impact:Results: Mothers in the MgSO4 group were more likely to have preeclampsia and antenatal steroid treatment, while their infants were younger in gestation and weighed less (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antenatal magnesium sulfate · Neonatal resuscitation · Patent ductus arterisus

Abstract

Background/Aim: Antenatal magnesium sulfate (MgSO4) treatment is widely used for fetal neuroprotection in women at risk of preterm delivery. Possible adverse effects of MgSO4 include respiratory depression and delay in closure of ductus arteriosus by antagonism of calcium channels. The aim of this study was to investigate the effects of antenatal MgSO4 exposure on cardiorespiratory complications during the early neonatal period in premature infants. Methods: A retrospective cohort study was performed on 340 preterm infants born between 23 and 32 weeks of gestational age. Patients were divided into two groups according to antenatal MgSO4 exposure: The MgSO4 group (n=186) and the no-MgSO4 group (n=154). Outcomes were acute cardiorespiratory events (intubation at birth, respiratory support, and hypotension in first day of life), and hemodynamically significant patent ductus arteriosus (HsPDA). Results: Mothers in the MgSO4 group were more likely to have preeclampsia and antenatal steroid treatment, while their infants were younger in gestation and weighed less (P

🔖

Cite This Article

ÜSTÜN, N., HOCAOĞLU, M., TURGUT, A., OVALI, F. (2021). Effects of antenatal magnesium sulfate use for neuroprotection on cardiorespiratory complications during the early neonatal period in preterm infants. Journal of Surgery and Medicine, Cilt: 5 - Sayı: 9, 843–847. https://ajindex.com/articles/779830

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Kruse M, Michelsen S, Flachs EM, Brønnum-Hansen H, Madsen M, Uldall P. Lifetime costs of cerebral palsy. Dev Med Child Neurol. 2009;51(8):622–8. doi: 10.1111/j.1469-8749.2008.03190.x
  2. Paneth N, Hong T, Korzeniewski S. The descriptive epidemiology of cerebral palsy. Clin Perinatol. 2006;33(2):251–67. doi: 10.1016/j.clp.2006.03.011
  3. Duley L, Gulmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2010;2010(9):CD002960. doi: 10.1002/14651858.CD002960.pub2
  4. Crowther CA, Hiller JE, Doyle LW, Haslam RR; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before pretermbirth: a randomized controlled trial. JAMA 2003; 290(20):2669–76. doi: 10.1001/jama.290.20.2669 5. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359 (9):895–905. doi: 10.1056/NEJMoa0801187
  5. Marret S,Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B, et al; le groupe PREMAG. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. Gynecol Obstet Fertil 2008;36(3):278–288. doi: 10.1016/j.gyobfe.2008.01.012
  6. Shepherd E, Salam RA, Middleton P, Makrides M, McIntyre S, Badawi N, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2017;8(8):CD012077. doi: 10.1002/14651858.CD012077.pub2 8. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010;115(3):669-671. doi: 10.1097/AOG.0b013e3181d4ffa5
  7. Narasimhulu D, Brown A, Egbert NM, Rojas M, Haberman S, Bhutada A, et al. Maternal magnesium therapy, neonatal serum magnesium concentration and immediate neonatal outcomes. J Perinatol. 2017;37(12):1297-1303. doi: 10.1038/jp.2017.132 10. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002;186 (6):1111-8. doi: 10.1067/mob.2002.123544
  8. Abbassi-Ghanavati M, Alexander JM, McIntire DD, Sa